News
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
18h
Everyday Health on MSNZebound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
2h
Zacks Investment Research on MSNSepterna Stock Surges on Oral Obesity Drug Deal With Novo NordiskShares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...
Taking semaglutide and liraglutide — a lesser-known active ingredient — medications for weight loss cut their consumption by nearly two-thirds in just four months. At such a critical moment in US ...
Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...
Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...
Ozempic side effects are a hot topic but don’t panic – our experts are here to help. Here’s what to expect and how to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results